Last updated 2026-07-25
TL;DR
The most common PT-141 (bremelanotide) side effects are nausea (up to about 40% of users in trials), flushing, headache, and injection site reactions. Nausea usually fades after the first couple of doses. Rare but serious effects include a temporary blood pressure spike and darkening of the skin or gums with repeated use. It works on brain receptors, not blood vessels, which explains this side effect pattern.
What are the most common PT-141 side effects?
Nausea is the single biggest complaint, and it's not close. In the phase 3 RECONNECT trials that got bremelanotide approved as Vyleesi, nausea showed up in about 40% of women on the drug versus roughly 1.3% on placebo, and it was the top reason people quit the studies [1]. Flushing came in second, affecting somewhere around 20% of users, with headache and injection site reactions (pain, redness, swelling, itching) rounding out the common list [2]. Most of this clusters in the first one or two doses. A safety pooling of the full clinical development program, covering thousands of exposures, found that nausea severity and frequency both tend to drop off with repeated use, which lines up with what prescribers see in practice [2]. If your first dose makes you queasy, that's typical, not a sign something is wrong. Here's the rough shape of it: nausea affects the most people but is rarely dangerous, flushing is uncomfortable but short-lived, and injection site reactions are a nuisance rather than a real problem for most users. None of these three require stopping the drug outright, though persistent vomiting is worth a call to whoever prescribed it.
Why does PT-141 cause nausea and flushing when Viagra doesn't?
This is the single most useful thing to understand about this drug. Bremelanotide doesn't touch blood vessels directly. It's a melanocortin receptor agonist that acts in the brain, primarily on MC4 receptors involved in sexual desire circuits, not on the vascular smooth muscle that PDE5 inhibitors like sildenafil target [3]. Sildenafil works locally, downstream, on blood flow. Bremelanotide works upstream, centrally, on wanting. That central mechanism is exactly why the side effect profile looks the way it does. Melanocortin receptors, especially MC4R, sit in brain regions that also regulate nausea, vomiting reflexes, and vascular tone through the autonomic nervous system, so turning them on for desire also nudges those other systems [4]. A neurobiology review describing bremelanotide's action ties the drug's effect on desire pathways in the hypothalamus directly to this broader receptor activity, which is the tradeoff of going central instead of local [5]. So the nausea and flushing aren't a manufacturing flaw or a dosing mistake. They're a direct consequence of where the drug acts. If you want more on how the mechanism actually works day to day, see our explainer on pt 141 peptide.
How common is nausea with bremelanotide, and does it get better?
In the two phase 3 RECONNECT trials (Reconnect Study 1 and Study 2), nausea was reported in roughly 39-40% of women taking bremelanotide compared to about 1-4% on placebo, and it was severe enough in some cases to cause discontinuation [6]. This is by far the most-cited number in the literature and the one prescribers quote most. The drug's safety pooling analysis, which combined data across the clinical development program, found that nausea incidence was highest after the first dose and declined with subsequent doses [2]. In practical terms, that means the worst dose for nausea is usually the very first one, and many women find it far more tolerable after their body adjusts. A few things reduce the odds of nausea being bad. Taking the dose on an empty-ish stomach isn't required, but many people report doing better without a heavy meal right before or after. Anti-nausea medication is sometimes used by prescribers for people with a strong reaction, though this isn't part of the official label. If nausea is severe or doesn't improve by the third or fourth dose, that's a conversation to have with the prescriber, not something to just push through indefinitely.
Does PT-141 raise blood pressure? What about heart rate?
Yes, transiently. Bremelanotide causes a temporary rise in blood pressure and a small drop in heart rate that peaks a few hours after dosing and resolves within about 12 hours [7]. This is a known, labeled effect, not a rare complication. Because of this, the drug carries specific cautions for people with uncontrolled high blood pressure or known cardiovascular disease. A review focused specifically on managing hypertension alongside female sexual dysfunction treatment flags bremelanotide's transient pressor effect as something to actively screen for before prescribing, particularly in women who already have blood pressure that isn't well controlled [8]. It's not a reason to panic if you have normal blood pressure, but it is a reason to be upfront with a prescriber about your cardiovascular history, and to have your blood pressure checked before starting. This is also part of why bremelanotide is capped at limited uses per month rather than daily use. The FDA label limits it to no more than one dose in 24 hours and no more than 8 doses per month, partly tied to this blood pressure effect and the need to let it resolve between doses [7].
Can PT-141 cause skin or gum darkening?
Yes, and this one is specific to repeated, long-term use rather than a single dose. Focal hyperpigmentation, meaning darkened patches of skin, particularly on the face, gums, or breasts, has been reported with repeated bremelanotide dosing and is called out directly in the drug's safety data [9]. The reason ties back to the same receptor family. Bremelanotide is related structurally to melanocyte-stimulating hormone, and melanocortin receptors (specifically MC1R) also regulate pigment production in skin cells [10]. So activating the broader melanocortin receptor family for its effect on desire can, with repeated exposure, also nudge pigment-producing cells. This effect can be permanent in some cases, which is why the label recommends discontinuing the drug if hyperpigmentation is noticed, especially before it becomes extensive. This side effect is uncommon compared to nausea or flushing, but it's the one that's hardest to reverse, so it deserves real attention rather than a shrug. If you notice new dark patches anywhere, especially on the face or gums, tell your prescriber before your next scheduled dose.
What side effects showed up in the phase 3 clinical trials?
| Nausea | ~39-40% | ~1-4% | |
|---|---|---|---|
| Flushing | ~20% | low single digits | |
| Headache | ~11% | lower, exact rate varies by trial | |
| Injection site reactions | reported in both trials | present but less frequent | |
| Vomiting | reported, smaller subset of nausea cases | rare | A separate responder analysis from an earlier phase 2b dose-ranging study found that side effect rates, especially nausea, tracked with dose size, meaning higher doses produced more nausea and flushing, which is part of why the approved dose (1.75 mg) sits where it does rather than higher [11]. If you're trying to understand where that number came from, our PT-141 dosage guide covers the approved dosing range in more detail. It's worth being honest that not everyone reads this data the same way. A critical re-analysis published in the Journal of Sex Research argued that the actual clinical benefit measured in these trials was modest relative to the side effect burden, and questioned whether the effect size justified the tradeoffs for the average patient [12]. That's a legitimate scientific debate, and it's one reason some clinicians present bremelanotide as one option among several rather than a first-line choice for everyone. |
The two RECONNECT phase 3 trials, both randomized and placebo-controlled, are the core evidence base behind the FDA approval, and their side effect data is the most reliable dataset available [6]. Here's how the major reported effects compare: | Side effect | Bremelanotide group | Placebo group |
Are PT-141 side effects different from flibanserin (Addyi) side effects?
Yes, meaningfully. Flibanserin is a daily pill that works on serotonin receptors and carries a boxed warning for severe low blood pressure and fainting, especially when mixed with alcohol. Bremelanotide is an as-needed injection that works on melanocortin receptors and instead causes a transient rise in blood pressure, not a drop [13]. A regulatory commentary comparing both drugs points out that they were approved through different evidence standards and carry genuinely different risk profiles, cautioning against treating them as interchangeable just because they're both marketed for low sexual desire in women [13]. In plain terms: if you can't tolerate alcohol restrictions or worry about fainting, bremelanotide's side effect profile (nausea, flushing, temporary blood pressure rise) may be more manageable for you than flibanserin's. If nausea is a dealbreaker, the reverse might be true. Neither drug is free of tradeoffs, and the choice usually comes down to which side effect profile fits your health history and lifestyle better.
Who should avoid PT-141 because of side effect risk?
The label and clinical literature point to a few clear groups where caution or avoidance makes sense. People with uncontrolled hypertension or known cardiovascular disease need real caution given the transient blood pressure spike, and this should be discussed with a prescriber who knows your history before starting [8]. People with a history of skin hyperpigmentation disorders, or strong concern about visible pigment changes, should weigh the risk of focal darkening with repeated use [9]. Anyone who has had a severe reaction to a prior dose, meaning persistent vomiting, fainting, or a dramatic blood pressure change, generally shouldn't just try again at the same dose without medical guidance. Bremelanotide is approved specifically for premenopausal women with hypoactive sexual desire disorder (HSDD), and the trial evidence doesn't extend cleanly to other populations, so anyone outside that group should have a real conversation about off-label use with a provider rather than assuming the safety data transfers directly [1].
How do you manage or reduce PT-141 side effects?
The single biggest lever is dose and injection site consistency. Sticking to the approved 1.75 mg subcutaneous dose, rather than experimenting with higher amounts, keeps nausea and flushing closer to the rates seen in trials rather than the higher rates seen at higher experimental doses [11]. Our guide on PT-141 injection sites and PT-141 how to inject cover technique specifics. Timing matters too. Dosing at least 45 minutes before anticipated activity, on an empty-ish stomach, is standard guidance, and many users report the nausea window passes before the drug's effects on desire kick in. Staying upright and hydrated after dosing can take the edge off flushing and lightheadedness for some people. Spacing doses out according to the label (no more than one dose in 24 hours, no more than 8 per month) isn't just a rule to prevent overuse. It also gives the temporary blood pressure rise time to fully resolve between doses [7]. If you're timing doses around a broader routine, our piece on PT-141 cycle length walks through spacing in more detail. If nausea remains severe after three or four doses despite following these steps, that's a real signal to reassess with a prescriber rather than push through it.
What does provider-reviewed access actually mean for side effect safety?
Because bremelanotide has a real, labeled side effect profile including a blood pressure effect and a rare but permanent pigmentation risk, working with a provider who screens your health history before prescribing is not a formality. It's the mechanism by which the known risks (hypertension, cardiovascular history, prior severe reactions) actually get caught before they become a problem [8][9]. Bremelanotide Rx works with a provider-reviewed pathway that connects patients to licensed prescribers and a fulfilling pharmacy partner, rather than compounding or manufacturing anything itself. That distinction matters here specifically because side effect management (blood pressure checks, dose titration, watching for pigmentation changes) depends on having an actual clinician involved, more than a supplier.
When should you stop PT-141 or call a doctor?
Stop and call your prescriber if you notice new dark patches on skin, gums, or breast tissue, since this is the side effect most likely to become permanent with continued use [9]. Persistent vomiting, rather than mild nausea, is also a reason to stop and reassess rather than push through to the next dose. A sudden, severe headache, chest pain, or a blood pressure reading that's unusually high for you after dosing warrants urgent attention given the drug's known transient pressor effect [7]. Fainting or a dramatic drop in heart rate is also not something to just monitor at home. Outside of these red flags, ordinary nausea, flushing, and injection site irritation that improve within the first day and lessen with repeated doses are within the expected range described in the phase 3 trial data [6]. When in doubt, a same-week call to your prescriber costs nothing and settles the question.
Frequently asked questions
Does PT-141 cause nausea every time you use it?
Not usually after the first couple of doses. Trial data shows nausea affects about 39-40% of users as a group, but it's most common and most intense with the first dose and tends to lessen with repeated use, according to safety pooling from the clinical development program [2]. Persistent nausea with every dose after several tries is worth discussing with a prescriber.
Is the flushing from PT-141 dangerous?
No, flushing from bremelanotide is uncomfortable but not dangerous on its own. It affects roughly 20% of users in trial data and typically resolves within hours [1]. It reflects the drug's action on melanocortin receptors involved in vascular tone, not a sign of an allergic reaction or cardiovascular event by itself.
Can PT-141 permanently darken my skin?
It can, in rare cases, with repeated use. Focal hyperpigmentation on the face, gums, or breast tissue has been reported and can persist even after stopping the drug [9]. This is why the label recommends discontinuation if pigment changes are noticed, and why watching for early signs matters more than for the other common side effects.
Why does PT-141 raise blood pressure instead of lowering it like Viagra?
Because it works through a completely different mechanism. Bremelanotide acts centrally on melanocortin receptors in the brain rather than on blood vessels directly, and this central action produces a transient rise in blood pressure and a small drop in heart rate for a few hours after dosing [7], unlike PDE5 inhibitors, which act locally on vascular tissue.
How long do PT-141 side effects last after a dose?
Most side effects, including nausea, flushing, and the transient blood pressure change, resolve within about 12 hours of dosing [7]. Injection site reactions like redness or mild swelling may linger slightly longer but typically clear within a day or two. Skin pigmentation changes, if they occur, are the exception and can persist longer term.
Is nausea worse at higher PT-141 doses?
Yes. A phase 2b dose-ranging study found that side effect rates, nausea in particular, increased with higher doses, which is part of why the FDA-approved dose for Vyleesi (1.75 mg subcutaneous) sits at a level chosen to balance effect against tolerability [11]. Taking more than the approved dose doesn't improve results and raises side effect risk.
Can men use PT-141, and are the side effects the same?
Bremelanotide is FDA-approved only for premenopausal women with hypoactive sexual desire disorder [1]. It has been studied in some male sexual dysfunction research, but there's no FDA-approved indication or dedicated large-scale safety dataset for men, so side effect rates in that population aren't established with the same confidence as the female HSDD data.
Does PT-141 interact badly with alcohol like Addyi does?
Bremelanotide doesn't carry the same alcohol-related fainting warning that flibanserin (Addyi) does. The two drugs have different mechanisms and different risk profiles, and a regulatory comparison specifically cautions against assuming their safety warnings are interchangeable [13]. Still, discuss alcohol use with your prescriber given bremelanotide's own blood pressure effects.
How many PT-141 doses per month are considered safe?
The FDA label limits bremelanotide to no more than one dose in 24 hours and no more than 8 doses per month [7]. This cap exists partly to let the transient blood pressure rise fully resolve between doses and partly because trial data doesn't cover safety beyond this frequency.
Will PT-141 side effects go away if I stop taking it?
Most side effects, nausea, flushing, headache, injection site irritation, and the blood pressure effect, resolve completely once you stop dosing, since they're tied to each individual dose rather than accumulating [2][7]. The one exception is skin or gum hyperpigmentation from repeated use, which can persist even after discontinuation in some cases [9].
Are injection site reactions from PT-141 common?
Yes, mild injection site reactions like redness, pain, itching, or swelling were reported in both phase 3 RECONNECT trials, though generally less frequent than nausea or flushing [6]. Rotating injection sites and using proper technique tends to reduce irritation over repeated use.
Does bremelanotide cause weight loss or weight changes as a side effect?
Two phase 1 randomized controlled trials looked specifically at bremelanotide's effect on body weight in obese women and found measurable effects on weight, tied to its action on melanocortin receptors that also regulate appetite and metabolism [14]. This isn't part of its approved indication or label for HSDD, but it reflects the same broader receptor mechanism.
Sources
- PubMed, Bremelanotide: First Approval (Drugs, 2019): Bremelanotide is FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women, and flushing affects roughly 20% of users in trial data
- PubMed, Safety Profile of Bremelanotide Across the Clinical Development Program (Journal of women's health, 2022): Nausea incidence and severity are highest after the first dose and decline with repeated use across the pooled clinical development program
- PubMed, Bremelanotide for Treatment of Female Hypoactive Sexual Desire (Neurology international, 2022): Bremelanotide acts as a melanocortin receptor agonist centrally rather than acting on vascular smooth muscle like PDE5 inhibitors
- PubMed, Ligands for Melanocortin Receptors: Beyond Melanocyte-Stimulating Hormones and Adrenocorticotropin (Biomolecules, 2022): Melanocortin receptors regulate multiple physiological systems beyond desire, including pigment production and autonomic functions
- PubMed, The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women (CNS spectrums, 2022): Bremelanotide's action on desire pathways in the hypothalamus is tied to its broader melanocortin receptor activity
- PubMed, Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials (Obstetrics and gynecology, 2019): In the RECONNECT phase 3 trials, nausea occurred in roughly 39-40% of bremelanotide users versus a low single-digit percentage on placebo, and was the leading cause of discontinuation
- PubMed, Bremelanotide (Vyleesi) for hypoactive sexual desire disorder (The Medical letter on drugs and therapeutics, 2019): Bremelanotide causes a transient rise in blood pressure and drop in heart rate resolving within about 12 hours, and is limited to one dose per 24 hours and 8 doses per month
- PubMed, Management of Hypertension with Female Sexual Dysfunction (Medicina, 2022): Bremelanotide's transient pressor effect requires screening in women with uncontrolled hypertension or cardiovascular disease before prescribing
- PubMed, Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder (The Annals of pharmacotherapy, 2020): Focal hyperpigmentation of skin, gums, or breast tissue has been reported with repeated bremelanotide use and can be persistent
- PubMed, Polymorphism of Melanocortin Receptor Genes-Association with Inflammatory Traits and Diseases (Diseases, 2025): Melanocortin receptors, including MC1R, regulate pigment production in skin cells, connecting the receptor family to pigmentation effects
- PubMed, Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide (The journal of sexual medicine, 2019): Side effect rates including nausea and flushing increased with higher doses in phase 2b dose-ranging data, informing the approved 1.75 mg dose
- PubMed, Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder (Journal of sex research, 2024): A critical re-analysis found the measured clinical benefit in bremelanotide trials was modest relative to its side effect burden
- PubMed, Bremelanotide and flibanserin for low sexual desire in women: the fallacy of regulatory precedent (Drug and therapeutics bulletin, 2021): Bremelanotide and flibanserin have different mechanisms and risk profiles and should not be treated as interchangeable based on regulatory precedent
- PubMed, Effect of bremelanotide on body weight of obese women: Data from two phase 1 randomized controlled trials (Diabetes, obesity & metabolism, 2022): Two phase 1 randomized controlled trials examined bremelanotide's effect on body weight in obese women, tied to melanocortin receptor activity on appetite